Novartis Bangladesh

What Novartis Bangladesh does

Novartis Bangladesh is the Bangladesh country operation of Novartis AG, a Swiss-headquartered, publicly listed innovative medicines company (NYSE: NVS, SIX: NOVN) that operates a global pharmaceutical business focused on four therapeutic areas: cardiovascular, renal and metabolic diseases; immunology; neuroscience; and oncology. The Bangladesh presence, headquartered in Dhaka and established in 1973, distributes the parent's prescription medicines through physicians, hospitals, and pharmacy networks, and participates in access programs such as Novartis Access and Healthy Family Programs that target chronic diseases in lower-income markets. Local operations serve patients, caregivers, and healthcare professionals, and connect to the parent's worldwide R&D, manufacturing, and clinical-trial infrastructure.

The company's product portfolio rests on differentiated technology platforms including CAR-T cell therapy (exemplified by Kymriah for B-cell ALL and DLBCL), AAV-based gene therapy (Zolgensma for spinal muscular atrophy delivered via Novartis Gene Therapies), and radioligand therapy with dedicated manufacturing in Carlsbad, California. Established commercial assets include Cosentyx (IL-17 inhibitor across psoriasis, psoriatic arthritis, and ankylosing spondylitis) and Entresto (heart failure). The parent runs an R&D organization of 8,000 employees in Europe and supports a pipeline that in mid-2026 produced readouts for Rhapsido in chronic inducible urticaria and delpacibart braxlosiran in FSHD.

Commercially, Novartis operates a sales-led go-to-market model reaching 296 million patients worldwide through healthcare professionals, hospitals, and pharmacies, supplemented by managed access programs (e.g., Zolgensma gMAP). Revenue mechanics are based on one-time prescription sales of innovative medicines across multiple geographies and therapeutic areas, with value-based and access-tier pricing in lower-income markets. Following the 2023 spinoff of Sandoz, Novartis AG is a pure-play innovative medicines company with wholly owned subsidiaries including Novartis Gene Therapies, supported by a quality management system certified to GMP/GDP, ICH, and PICS standards and conducting more than 1,000 third-party GxP supplier audits annually.

Name

Novartis Bangladesh

Legal name

Novartis AG

Website

https://novartis.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Novartis Bangladesh is the Bangladesh country operation of Novartis AG, a Swiss-headquartered innovative medicines company. It distributes branded prescription drugs across cardiovascular, immunology, neuroscience, and oncology therapeutic areas to patients, caregivers, and healthcare professionals via physicians, hospitals, and pharmacies.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Innovative pharmaceuticals
• Prescription medicines
• Oncology therapeutics
• Cardiovascular medicines
• Gene therapy

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Medicines: Novartis generates revenue through the discovery, development, and sale of innovative medicines addressing serious disease areas including cardiovascular, immunology, neuroscience, and oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Novartis Bangladesh is the Bangladesh country operation of Novartis AG, selling innovative prescription medicines across four therapeutic areas: cardiovascular, renal and metabolic diseases; immunology; neuroscience; and oncology. Its portfolio includes leading global brands such as Entresto (heart failure), Cosentyx (immunology), Kymriah (CAR-T cell therapy), and Zolgensma (gene therapy), distributed through healthcare professionals, hospitals, and pharmacy networks.

Product overview

Novartis is an innovative medicines company focused on reimagining medicine to improve and extend people's lives. The company offers a portfolio of products across four main therapeutic areas: cardiovascular, renal and metabolic diseases; immunology; neuroscience; and oncology. Key products include Kymriah (CAR-T cell therapy for blood cancers), Zolgensma (gene therapy for spinal muscular atrophy), Cosentyx (IL-17 inhibitor for immune diseases), and Entresto (heart failure treatment). The company operates through specialized divisions including Novartis Gene Therapies (gene therapies for rare diseases), technology platforms including radioligand therapy and CAR-T cell therapy, and access programs such as Novartis Access (affordable medicines for lower-income countries) and Healthy Family Programs. Novartis reaches 296 million people worldwide with its medicines.

Differentiator

Problem solved

Functional benefit

Brands

• Sandoz: A Novartis subsidiary focused on generic pharmaceuticals and biosimilars.
• Novartis Gene Therapies

Products and services

• Kymriah (tisagenlecleucel) CAR-T cell therapy approved for certain blood cancers including B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma; administered at qualified treatment centers.
• Zolgensma (onasemnogene abeparvovec) AAV-based gene therapy for spinal muscular atrophy (SMA) delivered via Novartis Gene Therapies, with access through the Zolgensma Global Managed Access Program (gMAP).
• Cosentyx (secukinumab) IL-17 inhibitor for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
• Entresto (sacubitril/valsartan) Heart failure medicine that reduces the risk of cardiovascular death and hospitalization.
• Novartis Gene Therapies portfolio Gene therapy products and manufacturing capabilities for rare diseases, operating as a sub-brand of Novartis.
• Radioligand Therapy (RLT) platform Targeted radiopharmaceutical treatments that deliver radiation directly to cancer cells, with manufacturing facilities in Carlsbad, California.
• CAR-T Cell Therapy platform Chimeric antigen receptor T-cell therapy platform for hematologic malignancies, with manufacturing facilities in the United States.
• Novartis Access Portfolio of affordable medicines for treating chronic diseases in lower-income countries.

Quantifiable outcome

• Medicines reach 296 million people worldwide
• +3 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Alliance for Regenerative Medicine (ARM)minorOthersARM is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)minorOthersEFPIA represents biopharmaceutical industry operating in Europe with direct membership of 36 national associations and 39 leading pharmaceutical companies.
• EucopeminorOthersEurope's trade body for innovative companies working in the field of pharmaceuticals and medical technologies active in research and development.
• EuropaBiominorOthersThe European Association for Bioindustries promotes an innovative and dynamic European biotechnology industry, representing 78 corporate, associate members and bioregions.
• Novartis FoundationcoreStrategic or Co-development PartnerNovartis Foundation operates as a strategic partner focusing on global health initiatives including malaria, leprosy, Chagas disease, sickle cell disease, and pandemic preparedness.
• Medicines for Malaria VenturecoreStrategic or Co-development PartnerPartnership to develop next-generation antimalarial treatments, expanding on Novartis commitment to malaria elimination.
• Novartis International Biocamp ParticipantsminorStrategic or Co-development PartnerAnnual innovation program bringing together future science leaders to explore new technologies in healthcare through collaboration and diversity.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Pfizer: Global innovative-medicines pharmaceutical major with overlapping therapeutic areas in oncology, cardiovascular, and rare disease. Direct competitor to Novartis in branded pharmaceuticals across multiple geographies including Bangladesh.
• Sanofi: European-headquartered innovative pharma peer competing in immunology, rare disease, and specialty therapeutics. Similar geographic footprint and a direct competitor in Bangladesh.
• Johnson & Johnson (Innovative Medicine): After the Kenvue separation, J&J's Innovative Medicine segment is a direct peer in oncology, immunology, and neuroscience. Similar blockbuster-revenue concentration and global distribution.
• Merck & Co. US-headquartered innovative pharma major with deep oncology (Keytruda) and vaccine franchises. Comparable scale, R&D intensity, and global commercial footprint, with overlapping Bangladesh market presence.
• Eli Lilly: US-headquartered innovative pharma major with growing presence in neuroscience, oncology, and immunology — direct overlap with Novartis therapeutic areas and similar blockbuster-driven model.
• Roche: Swiss-headquartered global pharma peer competing directly in oncology, immunology, and neuroscience. Similar scale, similar therapeutic breadth, and similar biologics manufacturing footprint make Roche the closest structural comparable.
• GSK: Global pharma major with established presence in Bangladesh and overlapping therapeutic areas in respiratory, immunology, and oncology. Comparable mid-large-cap innovative medicines business model.
• Bristol-Myers Squibb: Direct competitor in oncology (CAR-T with Breyanzi and Abecma competing with Kymriah) and immunology. Similar specialty-biologic profile and pipeline-driven growth thesis.
• AstraZeneca: Global pharma major with overlapping oncology, cardiovascular, renal and metabolic, and rare disease franchises. Direct competitor on multiple Novartis core therapeutic areas and active in Bangladesh.

Broad incumbents

• Bayer: Diversified German pharma major with overlapping cardiovascular and women's health franchises. Broader portfolio than Novartis post-Sandoz, but competes in similar therapeutic categories and markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/novartis

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Bangladesh